Stockscreener 앱 받기
0.131
1.28%
-0.0017
시간 외 거래:
.13
-0.001
-0.76%
Incannex Healthcare Inc 주식(IXHL)의 최신 뉴스
Incannex Healthcare Inc [IXHL] Revenue clocked in at $0.10 million, down -92.83% YTD: What’s Next? - dbtnews.com
It makes sense and dollars to buy Incannex Healthcare Inc (IXHL) stock - Sete News
Analyzing the Impact of Earnings Reports on Incannex Healthcare Inc Inc. (IXHL) Price Performance - investchronicle.com
Is Incannex Healthcare Inc (NASDAQ:IXHL) stock a better investment at this time? - uspostnews.com
Trading Day Review: Incannex Healthcare Inc (IXHL) Gains Momentum, Closing at 0.61 - DWinneX
Incannex Healthcare (NASDAQ:IXHL) Trading Down 19% – Here’s Why - Defense World
Incannex enters agreement for potential stock sales By Investing.com - Investing.com India
Incannex enters agreement for potential stock sales - Investing.com Australia
IXHL Stock Touches 52-Week Low at $0.64 Amid Market Challenges - Investing.com
Incannex Healthcare Completes Phase 2 Enrollment In Reposa Phase 2/3 Trial Of Ihl-42X, An Oral Once-Daily Treatment For Obstructive Sleep Apnea (Osa) - MarketScreener
Incannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA) - TradingView
Revolutionary Once-Daily Pill for Sleep Apnea Hits Major Clinical Trial Milestone - Stock Titan
IXHL stock touches 52-week low at $0.73 amid market challenges - Investing.com
Incannex Healthcare files to sell 65.97M shares of common stock for holders - MSN
Incannex Healthcare Inc. (NASDAQ:IXHL) Sees Significant Decrease in Short Interest - The AM Reporter
Incannex Healthcare Repays Convertible Debenture in Full - TipRanks
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
IXHL Stock Touches 52-Week Low at $0.73 Amid Market Challenges - Investing.com Australia
IXHL Stock Touches 52-Week Low at $0.73 Amid Market Challenges By Investing.com - Investing.com South Africa
Incannex Healthcare announces $12.5 million offering - Green Market Report
Incannex Healthcare Inc. Announces Pricing of $12.5 Million Private Placement Priced at the Market Under Nasdaq Rules - The Manila Times
Incannex Healthcare Inc. Announces Pricing Of $12.5 Million Private Placement Priced At The Market Under Nasdaq Rules - Marketscreener.com
Incannex Healthcare Inc. Announces $12.5 Million Offering of Common Stock and Series A Warrants - Nasdaq
Can This $12.5M Deal Push Incannex's Sleep Apnea Treatment to Phase 3? - StockTitan
IXHL stock touches 52-week low at $1.09 amid market challenges - Investing.com Australia
Incannex OSA Drug Candidate IHL-42X Sails Through Milestones - Sleep Review
IXHL stock touches 52-week low at $1.49 amid market challenges By Investing.com - Investing.com South Africa
IXHL stock touches 52-week low at $1.49 amid market challenges - Investing.com UK
Incannex Healthcare Limited Reports Quarterly Financials - TipRanks
Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2025 - The Kingston Whig-Standard
Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates - Defense World
Incannex Healthcare Reports Fiscal Second Quarter Results -February 14, 2025 at 08:49 am EST - Marketscreener.com
Incannex Healthcare Inc. SEC 10-Q Report - TradingView
Incannex Healthcare Appoints Alison Wimms, Ph.D. to its Newly Formed IHL-42X Obstructive Sleep Apnea Clinical Advisory Board - Defense World
Incannex Forms Clinical Advisory Board to Guide IHL-42X Sleep Apnea Drug Development - Sleep Review
Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board - The Manila Times
Incannex Healthcare Inc. Announces the Appointment of Alison Wimms as an Advisor to Its Newly Formed Ihl-42X Obstructive Sleep Apnea Clinical Advisory Board - Marketscreener.com
Sleep Medicine Pioneer Joins Incannex's Revolutionary OSA Treatment Development - StockTitan
Incannex Healthcare Announces Positive Topline Results from PK Study - Defense World
Incannex Reports Positive Data for OSA Drug Candidate IHL-42X - Sleep Review
Incannex Healthcare Announces Positive Topline Results from Pharmacokinetics (PK) Study of IHL-42X, an Oral Combination Medicine for the Treatment of Obstructive Sleep Apnea - The Manila Times
Incannex Reports Strong Results for Sleep Apnea Drug IHL-42X in Key Clinical Study - StockTitan
Incannex Healthcare faces Nasdaq delisting over market value By Investing.com - Investing.com South Africa
Incannex Healthcare faces Nasdaq delisting over market value - Investing.com
1.20%
0.06%
자본화:
|
볼륨(24시간):